Bristol Myers Squibb (BMS) has received approval from Health Canada for its dual immunotherapy combination for the treatment of two challenging gastrointestinal cancers. The newly approved therapy is indicated for patients with unresectable or advanced hepatocellular carcinoma (HCC), as well as another difficult-to-treat gastrointestinal cancer..

百时美施贵宝（BMS）已获得加拿大卫生部对其用于治疗两种具有挑战性的胃肠道癌症的双重免疫疗法组合的批准。新获批的疗法适用于无法切除或晚期肝细胞癌（HCC）患者，以及另一种难治性胃肠道癌症。

The approval marks the introduction of a dual immunotherapy option specifically designed to address these advanced cancer types, which often present limited treatment options. The decision by Health Canada follows evidence supporting the efficacy and safety of this combination therapy in managing these conditions..

该批准标志着引入了一种专门针对这些晚期癌症类型的双重免疫治疗选择，这些癌症通常治疗方案有限。加拿大卫生部的这一决定是基于支持这种组合疗法在管理这些疾病方面的有效性和安全性的证据。